Chemical inhibitors of SLC2A13 function through various mechanisms to impede its ability to transport glucose across cell membranes. It achieves this by blocking the glucose transport functions that SLC2A13 typically facilitates. Similarly, chemicals like WZB117 and STF-31, which are known for their inhibitory actions on GLUT1, can also inhibit SLC2A13. They do so by hindering glucose transport, thereby reducing glucose influx mediated by SLC2A13. Furthermore, Cytochalasin B directly binds to SLC2A13, obstructing the glucose transport pathway and thus inhibit the protein's function.
Moreover, BAY-876, by its nature of being a GLUT1 inhibitor, can occupy the binding sites on SLC2A13, resulting in competitive inhibition and prevention of glucose entry into the cell. Flavonoids such as Apigenin, Quercetin, and Luteolin operate by binding to the extracellular component of the transporter SLC2A13, altering its conformation and impairing glucose transport. Fasentin contributes to the inhibition of SLC2A13 by disrupting its intracellular trafficking, thus preventing its correct localization within the cell membrane which is essential for its function. The isoflavones Genistein and Daidzein also play a role in inhibiting SLC2A13. They might exert their inhibitory effect by binding directly to the transporter or by modifying its function, which in turn interferes with the protein's ability to conduct glucose molecules across the cell membrane. Resveratrol, another polyphenolic compound, can inhibit SLC2A13 by inducing conformational changes that impede the protein's glucose transport capabilities.